P2X and P2Y Receptors

TOCRIS bioscience

Kenneth A. Jacobson

Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA. Tel.: 301-496-9024, Fax: 301-480-8422, E-mail: kajacobs@helix.nih.gov

Kenneth Jacobson serves as Chief of the Laboratory of Bioorganic Chemistry and the Molecular Recognition Section at the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health in Bethesda, Maryland, USA. Dr. Jacobson is a medicinal chemist with interests in the structure and pharmacology of G-protein-coupled receptors, in particular receptors for adenosine and for purine and pyrimidine nucleotides.

Contents

Subtypes and Structures of P2 Receptor Families

The P2 receptors for extracellular nucleotides are widely distributed in the body and participate in regulation of nearly every physiological process.[1,2] Of particular interest are nucleotide receptors in the immune, inflammatory, cardiovascular, muscular, and central and peripheral nervous systems. The ubiquitous signaling properties of extracellular nucleotides acting at two distinct families of P2 receptors – fast P2X ion channels and P2Y receptors (G-protein-coupled receptors) – are now well recognized. These extracellular nucleotides are produced in response to tissue stress and cell damage and in the processes of neurotransmitter release and channel formation. Their concentrations can vary dramatically depending on circumstances. Thus, the state of activation of these receptors can be highly dependent on the stress conditions or disease states affecting a given organ. The P2 receptors respond to various extracellular mono- and dinucleotides (Table 1). The P2X receptors are more structurally restrictive than P2Y receptors in agonist selectivity. P2X receptors are activated principally by ATPs, while the P2Y receptors are activated by a group of five or more naturally occurring nucleotides.

The P2X receptors are distributed throughout the nervous system (autonomic, central, enteric and sensory neurons, cochlear and retinal cells), vascular system (cardiomyocytes, endothelium and smooth muscle), the pulmonary and digestive systems (epithelium and visceral smooth muscle), skeletal muscle, bone, and hematopoietic cells. The P2X receptors consist of trimeric ligand-gated ion channels. The subunits are numbered $P2X_1$ through $P2X_7$, and both heterotrimers and homotrimers occur. Activation of P2X receptors leads to influx of cations such as sodium and calcium, which depolarize excitable cells and activate cytosolic

enzymes respectively. The $P2X_7$ receptor upon prolonged agonist exposure also opens a large pore, which can pass organic cations and dye molecules. The knowledge of P2X receptor structures was recently advanced with the X-ray crystallographic determination of the $P2X_4$ subunit.[3,4] However, this structure did not establish the precise ligand binding site within the protein. A major difficulty in designing new agonist and antagonist ligands for a given P2X receptor subtype is that the homotrimers and heterotrimers may have entirely different structural requirements.

The correspondence of the P2Y receptor subtypes with their native nucleotide ligands is shown in Table 1.

The numbering of unique human P2Y receptors has some gaps – due to the fact that the assignment of numbers to certain putative P2Y receptors was later shown to be premature, with some of the previously designated sequences being P2Y species homologs and others being other types of receptors. Each of the native nucleotides may activate several P2Y receptor subtypes. The structures of representative adenine (Figure 1A, **1-10**) and uracil (Figure 1B, **11-28**) nucleotides that activate P2 receptors are shown. The adenine nucleotide ATP is a full agonist at two human P2Y subtypes ($P2Y_2$ and $P2Y_{11}$ receptors), and the corresponding diphosphate ADP activates three different subtypes ($P2Y_1$, $P2Y_{12}$, and $P2Y_{13}$

Table 1 | Subtypes of P2 receptors and their ligands (potency at the human homologs shown as *pEC$_{50}$*, unless noted r = rat)

Receptor	Main Distribution	Agonists (native in bold, *pEC$_{50}$*)	Antagonists
$P2X_1$	Smooth muscle, platelets, cerebellum, dorsal horn spinal neurons	BzATP *8.7* > **ATP** *7.3*, 2-MeSATP *7.3*, α,β-MeATP *6.7* (rapid desensitization) >> CTP *4.4*	NF 449 *9.5* > IP_5I *8.8* > TNP-ATP *8.2* > Ro 0437626 > NF 279 *7.7*
$P2X_2$	Smooth muscle, brain, pancreas, retina, chromaffin cells, autonomic and sensory ganglia	**ATP** *5.9*, 2-MeSATP *5.8* ≥ 2-MeSATP *5.8* >> α,β-MeATP <*4*	RB2 *6.4* (r), iso PPADS *6.4* (r) > PPADS *5.4* (r) > Suramin *4.5* (r)
$P2X_3$	Nociceptive sensory neurons, NTS, some sympathetic neurons	**ATP** *6.5*, 2-MeSATP *6.5* ≥ Ap_4A *6.3*, α,β-MeATP *6.1* (rapid desensitization)	TNP-ATP *9.0*, iso PPADS *7.1* > A317491 *7.6* > NF 110 *7.4* > PPADS *5.8*
$P2X_4$	Microglia, testis, colon, endothelial cells	**ATP** *6.3* >> α,β-MeATP *5.1* >> CTP *3.5*, Ivermectin (potentiates) *6.6*	5-BDBD >> TNP-ATP *4.8*, PPADS *4.6* > BBG *3.9* (r)
$P2X_5$	Proliferating cells in skin, gut, bladder, thymus, spinal cord, heart, adrenal medulla	ATPγS *6.2* (r), **ATP** *6.0* >> α,β-MeATP <*5.2*	BBG *6.3* > PPADS *5.6*, Suramin *5.4*
$P2X_6$	Brain, motor neurons in spinal cord	(no functional homomultimer)	–
$P2X_7$	Macrophages, mast cells, microglia, pancreas, skin, endocrine organs	BzATP *5.3* > **ATP** *4.0* ≥ 2-MeSATP >*4* >> α,β-MeATP >*4*	KN 62 *7.5*, BBG *8.0* (r)
$P2Y_1$	Brain, epithelial and endothelial cells, platelets, immune cells, osteoclasts	MRS 2365 *9.4* > 2-MeSADP *8.2* >> ADPβS *7.0* > **ADP** *5.1* > ATP	MRS 2500 *9.0* > MRS 2279 *7.3* > MRS 2179 *6.5*
$P2Y_2$	Immune cells, epithelial and endothelial cells, kidney tubules, osteoblasts	**UTP** *8.1*, MRS 2698 *8.1* ≥ **ATP** *7.1*, INS 365 *7.0* > INS 37217 *6.7*, UTPγS *6.6* > Ap_4A *6.1* > MRS 2768 *5.7*	AR-C 126313 *6* > Suramin *4.3* > RB2 >*4*
$P2Y_4$	Endothelial cells, placenta	2´-azido-dUTP *7.1* > UTPγS *5.8*, **UTP** *5.6* ≥ **ATP** *5.7* (rat), > Ap_4A *5.5* > CTP *5.2*, ITP *5.1*	ATP (human) *4.4* > RB2 >4 > Suramin >*4*
$P2Y_6$	Airway and intestinal epithelial cells, spleen, placenta, T-cells, thymus	MRS 2693 *7. 8* > UDPβS *7.3*, PBS 0474 *7.2* > INS 48823 *6.9*, Up_3U *6.6*, **UDP** *6.5* > UTP >> ATP	MRS 2578 *7.4* (noncompetitive) > RB2, PPADS
$P2Y_{11}$	Spleen, intestine, granulocytes	ATPγS *5.5* > ARC 67085MX *5.0* > BzATP *5.1* ≥ **ATP** *4.8*	NF 157 *7.4* > Suramin *4.8* > RB2 >*4*
$P2Y_{12}$	Platelets, brain (glial cells), microglial cells	2-MeSADP *7.9* ≥ **ADP** *7.2*	ARC 69931MX *8.4* > AZD 6140 *7.9*, INS 50589 *7.8* > RB2 *7.6* (r) > 2-MeSAMP *4.0*
$P2Y_{13}$	Spleen, brain, lymph nodes, bone marrow	**ADP** *7.9* = 2-MeSADP *7.9* > 2-MeSATP *7.1*, ATP *6.6*	ARC 69931MX *8.4* > ARC 67085 *6.7* > MRS 2211 *6.0*
$P2Y_{14}$	Placenta, mast cells, adipose tissue, stomach, intestine, discrete brain regions	MRS 2690 *7.3* > **UDP** *6.8*, **UDP-glucose** *6.5* > UDP-galactose *6.2*	–

receptors). The uracil nucleotide UTP activates two subtypes ($P2Y_2$ and $P2Y_4$ receptors), while UDP, previously thought to activate only a single subtype ($P2Y_6$ receptors), is now known to also activate $P2Y_{14}$ receptors along with the originally designated native agonist UDP-glucose.[5] The naturally occurring dinucleotide Ap_4A and its homologs also activate various P2 receptors.

The structure, signaling, and regulation of P2Y receptors have been explored, and subfamilies of $P2Y_1$-like and $P2Y_{12}$-like receptors have been defined. These subfamilies constitute two pharmacologically distinct groups of P2Y receptors that also correlate with similarities in the function of key amino acid residues.[6] The preferential coupling of the first subfamily of $P2Y_1$, $P2Y_2$, $P2Y_4$, $P2Y_6$, and $P2Y_{11}$ receptors is to G_q, leading to activation of phospholipase Cβ (PLCβ), and the the second subfamily of $P2Y_{12}$, $P2Y_{13}$, and $P2Y_{14}$ receptors couple to G_i resulting in the inhibition of adenylyl cyclase. $P2Y_{11}$ receptors also activate G_s to stimulate adenylyl cyclase. Comparisons of the structural characteristics and functionally important amino acid residues within the family have been described. Specific cationic residues and other residues in the TM region (e.g. Phe in TM3) and on the extracellular loops have conserved functions within the P2Y family. Molecular recognition in the $P2Y_1$, $P2Y_2$, $P2Y_{11}$, and $P2Y_{12}$ receptors has been extensively explored using mutagenesis.[7-10]

P2Y receptor regulation has also been studied. In platelets, which express two ADP-responsive P2Y subtypes, the $P2Y_1$ receptor is more rapidly desensitized than the $P2Y_{12}$ receptor.[11] The $P2Y_1$ receptor is desensitized mainly through PKC-dependent processes, and the $P2Y_{12}$ receptor is a good substrate for the GPCR kinases (GRKs) leading to arrestin binding. Residues on the cytosolic C-terminal domain involved in the regulation of the $P2Y_1$ receptor have been probed. The internalization of the $P2Y_{11}$ receptor is dependent on coexpression of the rapidly desensitizing $P2Y_1$ receptor, suggesting the occurrence of receptor dimers.[12] Various heterodimers of P2Y receptors with other P2Y and non-P2Y GPCRs have been proposed. For example, a dimer of A_1 adenosine receptors and $P2Y_1$ receptors was characterized.[13]

Recurrent issues in the use of typical P2 receptor ligands include cross-reactivity with multiple P2 receptors and low bioavailability, due to polyanions, such as phosphates and sulfonates, present in the molecules. Another drawback of many of the currently used ligands is lability in biological systems. A large family of ectonucleotidase enzymes hydrolyzes the native nucleotides leading to complications in interpretation of biological results. Adenine nucleotides are progressively converted enzymatically, in the last step by the action of CD73/5´-nucleotidase on AMP, to form adenosine, which activates its own family of four receptors. Selective inhibitors of ectonucleotidases which can serve as modulators of receptor function are being explored.[14] Moreover, many P2 receptor agonists and antagonists are known to inhibit ectonucleotidases at comparable concentrations. Known P2 antagonists often interact intracellularly with other signaling mediators, such as G proteins.

One reason for the relatively slow progress in identifying competitive antagonists of the P2 receptors is that there are few selective radioligands available for either the P2X or P2Y receptors. Previously, various radioactive nucleotides have been suggested to bind to particular P2 receptors, but many of these reports were later questioned, and currently only the $P2Y_1$, $P2Y_{12}$, $P2X_1$ and $P2X_3$ receptors have viable radioligands.[15-17] Thus, improved and more versatile affinity probes for the P2 receptors are still needed. New selective agonists and antagonists have recently been identified for some of the eight mammalian subtypes of P2Y receptors and for a few of the seven mammalian subtypes of P2X receptors. A careful probing of the structure activity relationships (SARs) at relevant P2 receptors has resulted in subtype-selective nucleotide agonists. Selective antagonist ligands for P2 receptors have been reported as a result of library screening, conversion of agonists into antagonists, and the careful structural modification of known non-selective ligands. The structures of representative nucleotide (Figure 2A, **29-42**) and non-nucleotide (Figure 2B, **43-73**) antagonists of the P2 receptors are shown.

Pharmacological Probes for P2X Receptors

The development of P2X receptor ligands for potential therapeutic application is underway. Selective P2X receptor antagonists are of interest in pain control, urinary incontinence, diabetic retinopathy, inflammatory diseases such as rheumatoid arthritis, and other conditions.

Non-Selective P2X Ligands

ATP activates all subtypes of P2X receptors, but at different concentrations varying from the low nanomolar to the high micromolar.[18] ADP and AMP, when purified, are inactive at P2X receptors. 2-Methylthioadenosine 5´-triphosphate (2-MeSATP) is a potent agonist at multiple P2X receptors, for example, $P2X_1$ (EC_{50} = 54 nM) and $P2X_3$ (EC_{50} = 350 nM) receptors. α,β-Methyleneadenosine 5´-triphosphate **6** activates and desensitizes the $P2X_1$ receptor and is inactive at the $P2X_2$ receptor. In tritiated form it serves as a radioligand of $P2X_1$ and $P2X_3$ receptors.

Figure 1A | Adenine derivatives that have been useful as antagonists in the study of P2 receptors



1 n = 2, **ATP** (Cat. No. 3245)
2 n = 1, ADP



3 Ap_4A



4 n = 2, **2-MeSATP** (Cat. No. 1062)
5 n = 1, **2-MeSADP** (Cat. No. 1624)



6 α,β-Methyleneadenosine 5´-triphosphate (Cat. No. 3209)



7 n = 3, ATPγS
8 n = 2



9 MRS 2365 (Cat. No. 2157)



10 Bz-ATP (Cat. No. 3312)

(Bold Text Denotes Compounds Available From Tocris)

$P2X_1$ Antagonist

NF 449
Cat. No. 1391



NF 449 is a potent purinergic receptor antagonist that displays high selectivity for $P2X_1$ (IC_{50} values are 0.28, 0.69, 120, 1820, 47,000 and > 300,000 nM for $rP2X_1$, $rP2X_{1+5}$, $rP2X_{2+3}$, $rP2X_3$, $rP2X_2$ and $P2X_4$ receptors respectively). The compound provides antithrombotic protection *in vivo*. NF 449 also acts as a $G_{s\alpha}$-selective antagonist.

Hohenegger *et al* (1998) $G_{s\alpha}$-selective G protein antagonists. Proc.Natl. Acad.Sci. ***95*** 346. **Hechler** *et al* (2005) Inhibition of platelet functions and thrombosis through selective or non-selective inhibition of the platelet P2 receptors with increasing doses of NF449 [4,4´,4´´,4´´´-(carbonylbis(imino-5,1,3-benzenetriylbis-(carbonylimino)))tetrakis-benzene-1,3-disulfonic acid octasodium salt]. J.Pharmacol.Exp.Ther. ***314*** 232. **Rettinger** *et al* (2005) Profiling at recombinant homomeric and heteromeric rat P2X receptors identifies the suramin analogue NF449 as a highly potent $P2X_1$ receptor antagonist. Neuropharmacology. ***48*** 461.

$P2X_1$ Antagonist

Ro 0437626
Cat. No. 2188



Ro 0437626 is a selective $P2X_1$ purinergic receptor antagonist (IC_{50} = 3 μM) that displays > 30-fold selectivity over $P2X_2$, $P2X_3$ and $P2X_{2/3}$ receptors (IC_{50} > 100 μM).

Jaime-Figueroa *et al* (2005) Discovery and synthesis of a novel and selective drug-like $P2X_1$ antagonist. Bioorg.Med.Chem.Lett. ***15*** 3292. **King** *et al* (2004) Investigation of the effects of P2 purinoceptor ligands on the micturition reflex in female urethane-anaesthetized rats. Br.J.Pharmacol. ***142*** 519. **Ford** *et al* (2006) Purinoceptors as therapeutic targets for lower urinary tract dysfunction. Br.J.Pharmacol. ***147*** S132.

Non-Selective P2X Ligands continued

Older, non-selective and weak P2X antagonists (Figures 2A and 2B), such as organic dyes **43** and **45**, have been in use for decades. The antiparasitic drug polysulfonated Suramin and the pyridoxal phosphate derivatives PPADS and positional isomer iso-PPADS are relatively nonsubtype-selective P2X antagonists, that also block some P2Y subtypes.[19] The PPADS analog MRS 2159 is more potent than PPADS at the $P2X_1$ receptor and also antagonizes the $P2X_3$ receptor. The nucleotide derivative TNP-ATP is a potent P2X antagonist that is selective

Figure 1B | Uracil derivatives that have been useful as antagonists in the study of P2 receptors



11 n = 2, UTP
12 n = **1, UDP** (Cat. No. 3111)



13 UDP-glucose



14 n = **3, UTPγS** (Cat. No. 3279)
15 n = 2, UDPβS



16 2-ThioUTP
(Cat. No. 3280)



17 n = 4, Up_4U, INS 365, Diquafosol
18 n = 3, Up_3U



19 MRS 2768
(Cat. No. 3884)



20 Up_4dC, INS 37217, Denufosol



21 MRS 2698



22



23 2´-azido-2´-deoxy-UTP



24 INS 48823



25 PSB 0474
(Cat. No. 2715)



26 MRS 2693



27 MRS 2690
(Cat. No. 2915)



28 MRS 2802

(Bold Text Denotes Compounds Available From Tocris)

for several subtypes.[20] It antagonizes $P2X_1$, $P2X_3$ and heteromeric $P2X_{2/3}$ receptors with IC_{50} values of 6, 0.9 and 7 nM respectively, and displays 1000-fold selectivity for $P2X_3$ over $P2X_2$, $P2X_4$ and $P2X_7$ receptors. The polysulfonated biphenyl derivative Evans Blue acts as a P2X receptor antagonist, but it also affects other channels and amino acid binding sites.

$P2X_1$ and $P2X_2$ Receptors

$P2X_1$ antagonists have been reported in several compound classes. For example, the Suramin derivative NF 157 is a $P2X_1$ antagonist that also blocks the $P2Y_{11}$ receptor.[22] Other Suramin derivatives that act as selective $P2X_1$ antagonists include: PPNDS, NF 279, and the more highly selective $P2X_1$ antagonist NF 449.[23,24] The earlier-reported Suramin analog NF 023 is a moderately selective, competitive P2X antagonist with IC_{50} values of 0.21 and 28.9 μM at human $P2X_1$ and $P2X_3$ receptors respectively, and is inactive at $P2X_2$ and $P2X_4$ receptors.[25] In a separate chemical series, the benzimidazole-2-carboxamide derivative Ro 0437626 was recently reported to be a selective $P2X_1$ antagonist (IC_{50} = 3 μM) that displays > 30-fold selectivity over $P2X_2$, $P2X_3$ and $P2X_{2/3}$ receptors (IC_{50} > 100 μM).[26] The dinucleotide Ip_5I was shown to antagonize the $P2Y_1$ receptor.[42] The pyridoxal phosphate derivative MRS 2219 is a weak potentiator of $P2X_1$-mediated responses.[27]

$P2X_4$ Receptor Antagonist

5-BDBD
Cat. No. 3579



5-BDBD is a potent $P2X_4$ receptor antagonist. The compound blocks $P2X_4$-mediated currents in Chinese hamster ovary cells (IC_{50} = 0.50 μM).

Donnelly-Roberts *et al* (2008) Painful purinergic receptors. J.Pharmacol.Exp. Ther. ***324*** 409.

There are no selective ligands for the $P2X_2$ receptor. The nonselective antagonists Suramin, TNP-ATP, RB-2, and isoPPADS have been used to study this receptor.

$P2X_3$ Receptor

The $P2X_3$ receptor may exist as a homotrimer or as a heterotrimer in combination with $P2X_2$ subunits. The Suramin derivative NF 110 is a high affinity $P2X_3$ receptor antagonist (K_i values are 36, 82 and 4140 nM for $P2X_3$, $P2X_1$ and $P2X_2$ receptors respectively) that is inactive at $P2Y_1$, $P2Y_2$ and $P2Y_{11}$ receptors (IC_{50} > 10 μM).

A major advance was the introduction of the competitive antagonist by Abbott Laboratories, A 317491, which blocks $P2X_3$ (IC_{50} = 22 nM) and $P2X_{2/3}$ (IC_{50} = 92 nM) receptors and is roughly three orders of magnitude selective for $P2X_3$ in comparison to $P2X_1$ and $P2X_2$ receptors.[17] A 317491 is inactive at $P2X_4$ receptors and at all P2Y receptors. Due to the presence of three carboxylic acid groups, A 317491 is of limited bioavailability. Another potent $P2X_3$ antagonist is the pyrimidinediamine derivative RO-3, which is a selective antagonist of the homomeric $P2X_3$ and heteromeric $P2X_{2/3}$ receptors (pIC_{50} values are 7.0 and 5.9 nM respectively) and is inactive at $P2X_1$, $P2X_2$, $P2X_4$, $P2X_5$ and $P2X_7$ receptors (IC_{50} > 10 μM).[29] The endogenous heptapeptide Spinorphin (LVVYPWT) was found to be a very potent $P2X_3$ antagonist (IC_{50} = 8.3 pM).[30]

$P2X_4$ Receptor

Few of the known P2X antagonists act at the $P2X_4$ receptor. The benzofurodiazepinone derivative 5-BDBD is an antagonist of $P2X_4$-mediated currents (IC_{50} = 0.50 μM).[31] The bacteria-derived broad spectrum antiparasitic agent Ivermectin, which is a macrocyclic lactone, is a positive allosteric modulator for the $P2X_4$ receptor, but it also affects other ion channels, such as nicotinic acetylcholine receptors.[32]

$P2X_5$ Receptor

There are no selective ligands for the $P2X_5$ and $P2X_6$ receptors. However, the dye Coomassie

$P2X_7$ Receptor Antagonists

A 438079
Cat. No. 2972



A 438079 is a competitive $P2X_7$ receptor antagonist (pIC_{50} = 6.9 for the inhibition of Ca^{2+} influx in the human recombinant $P2X_7$ cell line). The compound is devoid of activity at other P2 receptors (IC_{50} >> 10 μM). A 438079 possesses antinociceptive activity in models of neuropathic pain *in vivo*.

Nelson *et al* (2006) Structure-activity relationship studies on a series of novel, substituted 1-benzyl-5-phenyltetrazole $P2X_7$ antagonists. J.Med.Chem. ***49*** 3659. **Donnelly-Roberts and Jarvis** (2007) Discovery of $P2X_7$ receptor-selective antagonists offers new insights into $P2X_7$ receptor function and indicates a role in chronic pain states. Br.J.Pharmacol. ***151*** 571. **McGaraughty** *et al* (2007) $P2X_7$-related modulation of pathological nociception in rats. Neuroscience ***146*** 1817.

A 740003
Cat. No. 3701



A 740003 is a potent, selective and competitive $P2X_7$ receptor antagonist (IC_{50} values are 18 and 40 nM for rat and human receptors respectively). The compound displays selectivity over a variety of P2X and P2Y receptors up to a concentration of 100 μM. A 740003 reduces nociception in animal models of persistent neuropathic and inflammatory pain.

Honore *et al* (2006) A-740003 [N-(1-{[(cyanoimino)(5-quinolinylamino)methyl]amino}-2,2-dimethylpropyl)-2-(3,4-dimethoxyphenyl)acetamide], a novel and selective $P2X_7$ receptor antagonist, dose-dependently reduces neuropathic pain in the rat. J.Pharmacol.Exp.Ther. ***319*** 1376. **King** (2007) Novel $P2X_7$ receptor antagonists ease the pain. Br.J.Pharmacol. ***151*** 565. **Donnelly-Roberts** *et al* (2009) Mammalian P2X7 receptor pharmacology: comparison of recombinant mouse, rat and human P2X7 receptors. Br.J.Pharmacol. ***157*** 1203.

AZ 10606120
Cat. No. 3323



AZ 10606120 is a potent $P2X_7$ receptor antagonist (K_D values are 1.4 and 19 nM at human and rat $P2X_7$ receptors respectively). The compound binds in a positive cooperative manner to sites distinct from, but coupled to, the ATP binding site and acts as a negative allosteric modulator.

Michel *et al* (2007) Direct labelling of the human $P2X_7$ receptor and identification of positive and negative cooperativity of binding. Br.J.Pharmacol. ***151*** 103. **Michel and Fonfria** (2007) Agonist potency at $P2X_7$ receptors is modulated by structurally diverse lipids. Br.J.Pharmacol. ***152*** 523. **Michel** *et al* (2008) Negative and positive allosteric modulators of the $P2X_7$ receptor. Br.J.Pharmacol. ***153*** 737.

(Sold for research purposes under agreement from AstraZeneca)

$P2X_7$ Allosteric Modulator

GW 791343
Cat. No. 3385



GW 791343 is a $P2X_7$ allosteric modulator. The compound exhibits species-specific activity and acts as a negative allosteric modulator of human $P2X_7$ (pIC_{50} = 6.9 - 7.2) and a positive allosteric modulator of rat $P2X_7$.

Michel *et al* (2008) Negative and positive allosteric modulators of the $P2X_7$ receptor. Br.J.Pharmacol. ***153*** 737. **Michel** *et al* (2008) Identification of regions of the $P2X_7$ receptor that contribute to human and rat species differences in antagonist effects. Br.J.Pharmacol. ***155*** 738.

Brilliant blue G (BBG) has been used effectively to block $P2X_5$ receptor function (IC_{50} = 0.5 μM),[33] but this dye also blocks $P2X_4$ receptors (IC_{50} = 3 μM at human receptors) and $P2X_7$ receptors (IC_{50} values are 10 nM and 267 nM at rat and human receptors respectively).

$P2X_7$ Receptor

2′(3′)-*O*-(4-Benzoylbenzoyl)adenosine-5′-triphosphate (BzATP) is a $P2X_7$ receptor agonist that exhibits an order of magnitude greater potency than ATP. It is also a partial agonist at $P2X_1$ (pEC_{50} = 8.7) and $P2Y_1$ receptors.[34] One of the first antagonists of the $P2X_7$ receptor identified was the tyrosine and isoquinoline derivative KN-62, but it acts in a non-competitive fashion and is inactive at the rat $P2X_7$ homolog. KN-62 is also an inhibitor of CaM kinase II.[35] Oxidized-ATP (o-ATP) has also been used extensively to antagonize $P2X_7$ receptors.

Figure 2A | Nucleotide derivatives useful as antagonists in the study of the P2 receptors



29 R = H **MRS 2179** (Cat. No. 0900)
30 R = Cl MRS 2216



31 R = Cl **MRS 2279** (Cat. No. 2158)
32 R = I **MRS 2500** (Cat. No. 2159)



33 MRS 2298



34 TNP-ATP
(Cat. No. 2464)



35 AR-C 67085



36 AR-C 69931MX
Cangrelor



37 AZD 6140
Ticagrelor



38



39 INS 49266



40 INS 50589



41 Ip_5I



42 o-ATP

(Bold Text Denotes Compounds Available From Tocris)

It has been a challenge to identify antagonists that block the $P2X_7$ receptor in a species-independent manner. The tetrazolylmethylpyridine derivative A 438079 is a potent, selective, and competitive $P2X_7$ antagonist (pIC_{50} = 6.9).[36] The quinolinamino derivative A 740003 is a potent and selective competitive $P2X_7$ receptor antagonist (IC_{50} values are 40 and 18 nM for human and rat $P2X_7$ receptors respectively) that is also highly selective in comparison to various P2X and P2Y receptors.[36,37] The adamantyl derivative from AstraZeneca AZ 10606120 antagonizes the $P2X_7$ receptor with K_D values of 1.4 and 19 nM at human and rat $P2X_7$ receptors respectively.[38] The biphenyl derivative AZ 11645373 potently antagonized the human $P2X_7$ receptor in a non-surmountable manner with KB values ranging from 5-20 nM and was inactive at the rat $P2X_7$ receptor and at all other P2X subtypes.[39] The substituted glycyl anilide derivative GW 791343 is a positive allosteric modulator of the rat $P2X_7$ receptor and a negative allosteric modulator of the human $P2X_7$ receptor (pIC_{50} = 6.9-7.2).[40]

Pharmacological Probes for P2Y Receptors

There has been progress in the development of selective agonist and antagonist ligands for P2Y receptors for preclinical development.[2] Until recently, the only P2Y receptor ligand in pharmaceutical use was the antithrombotic $P2Y_{12}$ receptor antagonist Clopidogrel (Plavix).[41] Therefore, there is much activity to identify newer agents to act at the $P2Y_{12}$ receptor and at other P2Y receptors for pharmaceutical development. The rapidly accelerating progress in this field has already resulted in new drug candidates for pulmonary diseases, dry eye disease, and thrombosis.

$P2Y_1$ Agonist

MRS 2365
Cat. No. 2157



MRS 2365 is a highly potent, selective $P2Y_1$ receptor agonist (EC_{50} = 0.4 nM). The compound displays no activity at $P2Y_{12}$ receptors and only very low agonist activity at $P2Y_{13}$ receptors (at concentrations up to 1 μM).

Ravi *et al* (2002) Adenine nucleotide analogues locked in a northern methanocarba conformation: enhanced stability and potency as $P2Y_1$ receptor agonists. J.Med.Chem. ***45*** 2090. **Chhatriwala** *et al* (2004) Induction of novel agonist selectivity for the ADP-activated $P2Y_1$ receptor versus the ADP-activated $P2Y_{12}$ and $P2Y_{13}$ receptors by conformational constraint of an ADP analog. J.Pharmacol.Exp.Ther. ***311*** 1038.

(Sold under license from the NIH, US Patent 10/169975.)

$P2Y_1$ Antagonists

MRS 2179
Cat. No. 0900



MRS 2179 is a competitive antagonist at $P2Y_1$ receptors (K_B = 100 nM). The compound is selective over $P2X_1$ (IC_{50} = 1.15 μM), $P2X_3$ (IC_{50} = 12.9 μM), $P2X_2$, $P2X_4$, $P2Y_2$, $P2Y_4$ and $P2Y_6$ receptors.

Boyer *et al* (1998) Competitive and selective antagonism of $P2Y_1$ receptors by N^6-methyl 2´-deoxyadenosine 3´,5´-bisphosphate. Br.J.Pharmacol. ***124*** 1. **Moro** *et al* (1998) Human $P2Y_1$ receptor molecular modeling and site-directed mutagenesis as tools to identify agonist and antagonist recognition sites. J.Med. Chem. ***41*** 1456. **Nandanan** *et al* (2000) Synthesis, biological activity, and molecular modeling of ribose-modified deoxyadenosine bisphosphate analogues as $P2Y_1$ receptor ligands. J.Med.Chem. ***43*** 829. **Brown** *et al* (2000) Activity of novel adenine nucleotide derivatives as agonists and antagonists at recombinant rat P2X receptors. Drug Dev.Res. ***49*** 253.

MRS 2500
Cat. No. 2159



MRS 2500 is a highly potent and selective antagonist of the platelet $P2Y_1$ receptor (K_i = 0.78 nM). The compound inhibits ADP-induced aggregation of human platelets with an IC_{50} value of 0.95 nM. MRS 2500 prevents thrombus formation *in vivo*.

Kim *et al* (2003) 2-Substitution of adenine nucleotide analogues containing a bicyclo[3.1.0]hexane ring system locked in a northern conformation: enhanced potency as $P2Y_1$ receptor antagonists. J.Med.Chem ***46*** 4974. **Cattaneo** *et al* (2004) Antiaggregatory activity in human platelets of potent antagonists of the $P2Y_1$ receptor. Biochem.Pharmacol. ***68*** 1995. **Hechler** *et al* (2006) MRS2500 [2-iodo-*N*^{6}-methyl-(*N*)-methanocarba-2´-deoxyadenosine-3´ ,5´-bisphosphate], a potent, selective, and stable antagonist of the platelet $P2Y_1$ receptor with strong antithrombotic activity in mice. J.Pharmacol.Exp.Ther. ***316*** 556.

(Sold under license from the NIH, US Patent 60/029,855.)

Many selective ligand probes, both agonists and antagonists of the P2Y receptors, are now available. However, some subtypes, such as the $P2Y_4$ receptor, are entirely lacking such selective ligands. Detailed SAR analyses have been constructed for $P2Y_1$ and $P2Y_{12}$ receptors, which are both proaggregatory in platelets. Nucleotide agonists selective for $P2Y_1$, $P2Y_2$, $P2Y_6$, and $P2Y_{14}$ receptors and nucleotide antagonists selective for $P2Y_1$ and $P2Y_{12}$ receptors have been described. Selective non-nucleotide antagonists are now sought to avoid issues of limited stability and bioavailability. Such antagonists have been reported for $P2Y_1$, $P2Y_2$, $P2Y_6$, $P2Y_{11}$, $P2Y_{12}$, and $P2Y_{13}$ receptors. The screening of chemically diverse compound libraries has resulted in competitive $P2Y_{12}$ receptor antagonists that are being tested as potential antithrombotic agents.

$P2Y_1$ Receptor

2-MeSADP, like ADP, activates the $P2Y_1$, $P2Y_{12}$ and $P2Y_{13}$ receptors. 2-MeSADP is a more potent agonist at the $P2Y_1$ receptor than 2-MeSATP. N^6-methyl nucleotides are tolerated at the $P2Y_1$ receptor, consistent with a small hydrophobic pocket in the $P2Y_1$ receptor binding site surrounding the N^6-position of adenine nucleotides. The favored ribose-ring conformation for each of the subtypes of the $P2Y_1$-like subfamily has been established using conformationally-restricted (i.e. rigid) ribose equivalents, which also improve stability of the phosphate esters toward nucleotidases. In particular, the methanocarba ring system consisting of fused cyclopropane and cyclopentane has been useful in exploring the biologically active conformations of nucleoside and nucleotide derivatives. The North (N)-methanocarba analog of 2-MeSADP, MRS 2365 (EC_{50} = 0.4 nM), is a selective, high affinity agonist of the $P2Y_1$ receptor.[11] Another means of improving hydrolytic stability is the introduction of a borano group within the phosphate moiety of P2Y receptor agonists.[43]

Many nucleotide antagonists of the $P2Y_1$ receptor have been introduced. Usually these are adenine nucleotides containing bisphosphate groups, for example a ribose 3′,5′-bisphosphate moiety. A N^6-methyl 2′-deoxyadenosine bisphosphate derivative MRS 2179 (pK_B = 6.99) and its 2-chloro analog MRS 2216 are selective $P2Y_1$ antagonists.[44] The same (N)-conformational constraint of the ribose moiety that enhances agonist action also favors the potency and selectivity in nucleotide antagonists. For example, the ring-constrained (N)-methanocarba nucleotide bisphosphates MRS 2279 (pK_B = 8.10) and MRS 2500 (pK_B = 9) are selective, high affinity antagonists of the $P2Y_1$ receptor.[45] The antithrombotic action of MRS 2500 (by blocking the $P2Y_1$ receptor selectively) has been demonstrated *in vivo* in the mouse and other species.[46,47] Antagonists of the $P2Y_1$ receptor of moderate affinity may also be derived from acyclic nucleotides, such as the bisphosphates derivative MRS 2298.[46]

Non-nucleotide antagonists of the $P2Y_1$ receptor have been discovered through screening of structurally diverse chemical libraries. The first such compound to be reported was **63**, which is a selective and orally bioavailable antagonist of the human $P2Y_1$ receptor from Pfizer of novel chemotype with a K_i value of 90 nM.[48] Other structurally diverse antagonists of the $P2Y_1$ receptor have been reported. Pyridyl isatogen (PIT) is an allosteric modulator of the $P2Y_1$ receptor that displays mixed antagonism/potentiation.[49]

$P2Y_2$ Agonist

2-ThioUTP tetrasodium salt
Cat. No. 3280



2-ThioUTP is a potent and selective $P2Y_2$ agonist. EC_{50} values are 0.035, 0.35 and 1.5 μM for $hP2Y_2$, $hP2Y_4$ and $hP2Y_6$ receptors respectively.

El-Tayeb *et al* (2006) Synthesis and structure-activity relationships of uracil nucleotide derivatives and analogues as agonists at human $P2Y_2$, $P2Y_4$ and $P2Y_6$ receptors. J.Med.Chem. ***49*** 7076. **Ko** *et al* (2008) Synthesis and potency of novel uracil nucleotides and derivatives as $P2Y_2$ and $P2Y_6$ receptor agonists. Bioorg.Med.Chem. ***16*** 6319.

$P2Y_2$ and $P2Y_4$ Receptors

Both $P2Y_2$ and $P2Y_4$ receptors are activated by UTP, and simple modifications enhance selectivity for the $P2Y_2$ receptor. UTPγS is a more selective and stable agonist of the $P2Y_2$ receptor than UTP.[50] However, this compound is subject to chemical oxidation. 2-ThioUTP is also a selective agonist of the $P2Y_2$ receptor.[51] Combination of modifications of UTP in the selective $P2Y_2$ agonist MRS 2698 provided an EC_{50} of 8 nM and selectivity of 300-fold in comparison to the $P2Y_4$ receptor.[52]

Certain dinucleoside tetraphosphates potently activate the $P2Y_2$ and $P2Y_4$ receptors. The uracil dinucleotides that have been in clinical trials are Up_4U (INS 365, Diquafosol, EC_{50} = 0.1 μM) and Up_4dC (INS 37217, Denufosol, EC_{50} = 0.22 μM) .[53] Diquafosol was recently approved in Japan for use in treating dry eye. By virtue of being dinucleotides, they are more stable to enzymatic hydrolysis than nucleoside triphosphates, but these agonists are non-selective compared to the $P2Y_4$ receptor. The 2′-deoxycytidine (dC) moiety of **20** serves to enhance the *in vivo* stability toward ectonucleotidases. The agonist MRS 2768 (uridine tetraphosphate δ-phenyl ester) is selective for the $P2Y_2$ receptor with moderate potency (EC_{50} = 1.89 μM).[54]

$P2Y_6$ Agonist

PSB 0474
Cat. No. 2715



PSB 0474 is a potent and selective $P2Y_6$ receptor agonist. EC_{50} values are 70, > 1000 and > 10,000 nM for $P2Y_6$, $P2Y_2$ and $P2Y_4$ receptors respectively.

El-Tayeb *et al* (2006) Synthesis and structure-activity relationships of uracil nucleotide derivatives and analogues as agonists at human $P2Y_2$, $P2Y_4$ and $P2Y_6$ receptors. J.Med.Chem. ***49*** 7076.

Figure 2B | Non-nucleotides that have been useful antagonists in the study of P2 receptors



43 R= SO_3Na m- and p-mixture Reactive Blue 2



44 PSB 0739



45 Coomassie brilliant blue G (BBG)



46 R = **CH_3 Suramin** (Cat. No. 1472)
47 R = F **NF 157** (Cat. No. 2450)



48 NF 023 (Cat. No. 1240)



49 NF 279 (Cat. No. 1199)

R' =





50 NF 449 (Cat. No. 1391)

R'' =



51 NF 110 (Cat. No. 2548)

R'' =





R =



52 PPADS (Cat. No. 0625)



53 iso PPADS (Cat. No. 0683)



54 MRS 2159 (Cat. No. 1388)



55 MRS 2211 (Cat. No. 2402)



56 MRS 2219 (Cat. No. 1203)



57 AR-C 126313



58 AR-C 118925



59 PIT (Cat. No. 1682)



60 MRS 2578 (Cat. No. 2146)



61 Clopidogrel (Cat. No. 2490)



62 Prasugrel



63



64 Ro 0437626 (Cat. No. 2188)

(Bold Text Denotes Compounds Available From Tocris)

Figure 2B continued | Non-nucleotides that have been useful antagonists in the study of P2 receptors



(Bold Text Denotes Compounds Available From Tocris)

Definitive antagonists of the $P2Y_2$ receptor are not available. AR-C 126313 and its higher molecular weight analog AR-C 118925 were reported to selectively antagonize the $P2Y_2$ receptor, however it appears that these compounds are only micromolar in affinity (Figure 2B).[55] The large polyanionic molecules Reactive blue 2 (RB2, an anthraquinone dye) and Suramin are slightly selective antagonists of the $P2Y_2$ and $P2Y_4$ receptors, respectively. However, RB2 and Suramin also block various P2X receptors (Table 1).

There are no truly selective ligands for the $P2Y_4$ receptor. The agonist 2´-azido-2´-deoxy-UTP **23** displayed 5-fold $P2Y_4$ selectivity.[51] Thus, new agonists and antagonists are needed to distinguish this subtype pharmacologically from the $P2Y_2$ receptor, which is also activated by UTP. The other native agonist of the $P2Y_2$ receptor, ATP, acts as an antagonist at the human, but not the rat, $P2Y_4$ receptor.

$P2Y_6$ Receptors

UDP activates both the $P2Y_6$ and $P2Y_{14}$ receptors. It is worth noting, however, that extracellular UDP can serve as a substrate for the generation of UTP through the action of nucleoside diphosphokinase (NDPK), which may complicate pharmacological

$P2X_1$ / $P2Y_{11}$ Antagonist

NF 157
Cat. No. 2450



NF 157 is a purinergic receptor antagonist that potently inhibits $P2Y_{11}$ receptor activity (IC_{50} = 463 nM). The compound displays selectivity for $P2Y_{11}$ and $P2X_1$ receptors over $P2Y_1$, $P2Y_2$, $P2X_2$, $P2X_3$, $P2X_4$ and $P2X_7$ receptors. NF 157 inhibits NAD+-induced activation of human granulocytes.

Ullmann *et al* (2005) Synthesis and structure-activity relationships of suramin-derived $P2Y_{11}$ receptor antagonists with nanomolar potency. J.Med.Chem. ***48*** 7040. **Moreschi** *et al* (2006) Extracellular NAD+ is an agonist of the human P2Y11 purinergic receptor in human granulocytes. J.Biol.Chem. ***281*** 31419.

studies. The action of UPD at the $P2Y_{14}$ receptor has been controversial. UDP was initially described as inactive at the newly cloned $P2Y_{14}$ receptor, however later study found an antagonist action of UDP at the human but not rat $P2Y_{14}$ receptor. Finally the observed antagonist action of UDP was shown to occur in cells expressing an unnatural, engineered chimeric G protein. However, in HEK293 and other cells in which endogenous G_i proteins mediate the functional response, UDP acts as a potent agonist.[5] Thus, inaccurate results might be obtained using UDP alone in pharmacological studies if multiple P2Y subtypes are present. UDPβS and Up_3U have been used as more stable activators of the $P2Y_6$ receptor subtype than UDP,[50,53] although **15** also activates the $P2Y_{14}$ receptor.

The SAR of nucleotide derivatives in activating the $P2Y_6$ receptor has been explored. Certain dinucleoside triphosphates have been explored as $P2Y_6$ receptor ligands, for example, INS 48823 (EC_{50} = 125 nM) potently activates the receptor.[56] Other UDP derivatives, e.g. 3-phenacyl UDP (PSB 0474) and 5-iodo-UDP (MRS 2693), are selective $P2Y_6$ agonists with EC_{50} values of 70 and 15 nM respectively.[57,58] Molecular modeling predicted that the South (S)-conformation of the ribose ring is the preferred conformation in receptor binding, which was then confirmed by synthesis of a conformationally constrained methanocarba analog of UDP. The non-competitive $P2Y_6$ receptor antagonist MRS 2578 is a diisothiocyanate derivative, which has low stability and solubility in aqueous medium.[59] Competitive antagonists of the $P2Y_6$ receptor have not yet been reported.

$P2Y_{11}$ Receptors

ATPγS (Figure 1A) acts as a potent $P2Y_{11}$ receptor agonist. The $P2Y_{12}$ antagonist 2-propylthio-β,γ-dichloromethylene-ATP (AR-C 67085, Figure 2A) is also the most potent reported agonist of the $P2Y_{11}$ receptor (EC_{50} = 8.9 μM).[60] Thus, it must be used with caution in pharmacological studies in which both P2Y subtypes might be present.

A potent antagonist NF 157, derived from non-selective P2 antagonist Suramin, has been reported to be a selective antagonist of the $P2Y_{11}$ receptor (pK_i = 7.35).[61] However, this compound also antagonizes the $P2X_1$, $P2X_2$, and $P2X_3$ receptors.

$P2Y_{12}$ Receptors

The medicinal chemistry of the $P2Y_{12}$ receptor has been extensively explored. The thienopyridines, such as Clopidogrel (Figure 2B), act as liver-activated prodrugs that are irreversible inhibitors of the $P2Y_{12}$ receptor.[62] This thienopyridine $P2Y_{12}$ receptor antagonist requires a two-step preactivation *in vivo* and therefore has a delayed onset of action and long reversal of the platelet effect after drug administration is stopped. Another thienopyridine antagonist that has been in clinical trials, Prasugrel is a more potent $P2Y_{12}$ antagonist, but displays a longer bleeding time. Prasugrel only requires one step of preactivation *in vivo*.[63]

Directly-acting $P2Y_{12}$ receptor antagonists have also been reported. The observation that ATP acts as an antagonist at this ADP-activated subtype has enabled the introduction of various 5´-triphosphate analogs as selective receptor probes and clinical candidates. Thus, the antithrombotic nucleotide derivatives from AstraZeneca AR-C 67085 (EC_{50} = 30 μM) and AR-C 69931MX (Cangrelor, EC_{50} = 0.4 nM) have been tested clinically as antithrombotic agents.[64] A 5´-triphosphate group in adenine nucleotides is not strictly required for $P2Y_{12}$ receptor antagonists, as in the case of compound **38** and the potent antagonist and clinical candidate AZD 6140 (pIC_{50} = 7.9).[64,65] Other nucleotide antagonists of the $P2Y_{12}$ receptor that have been reported are nucleotide derivatives from Inspire Pharmaceuticals, INS 49266 (an ADP derivative with EC_{50} of 52 nM) and INS 50589 (an AMP derivative with EC_{50} of 11 nM).[66] Library screening has aided greatly in the identification of novel chemotypes that act as $P2Y_{12}$ receptor antagonists, and several of these compounds are being developed by the pharmaceutical industry. One very potent and selective competitive antagonist of the $P2Y_{12}$ receptor, PSB 0739, derived from RB2 was recently reported.

$P2Y_{13}$ Receptors

ADP is also the preferred agonist ligand at the $P2Y_{13}$ receptor, and ATP is less potent. In the rat, ADP is 3-5-fold more potent than 2-MeSADP. A selective $P2Y_{13}$ receptor antagonist, MRS 2211, a derivative of PPADS, has a pK_i of 6.0 at this receptor.[67]

$P2Y_{12}$ Antagonist

AR-C 66096
Cat. No. 3321



AR-C 66096 is a potent and selective $P2Y_{12}$ receptor antagonist. The compound blocks ADP-induced inhibition of adenylyl cyclase *in vitro* (pK_B =7.6) and inhibits ADP-induced aggregation of washed human platelets (pIC_{50} = 8.16).

Humphries *et al* (1994) FPL 66094: a novel, highly potent and selective antagonist at human platelet P_{2T}-purinoceptors. Br.J.Pharmacol. ***113*** 1057. **Ingall** *et al* (1999) Antagonists of the platelet P receptor: a novel approach to antithrombotic therapy. J.Med.Chem. ***42*** 213. **Simon** *et al* (2001) Activity of adenosine diphosphates and triphosphates on a $P2Y_T$-type receptor in brain capillary endothelial cells. Br.J.Pharmacol. ***132*** 173.

(Sold for research purposes under agreement from AstraZeneca)

$P2Y_{13}$ Antagonist

MRS 2211
Cat. No. 2402



MRS 2211 is a competitive $P2Y_{13}$ receptor antagonist (pIC_{50} = 5.97). The compound displays > 20-fold selectivity over $P2Y_1$ and $P2Y_{12}$ receptors.

Kim *et al* (2005) Synthesis of pyridoxal phosphate derivatives with antagonist activity at the $P2Y_{13}$ receptor. Biochem.Pharmacol. ***70*** 266. **Kugelgen** (2006) Pharmacological profiles of cloned mammalian P2Y-receptor subtypes. Pharmacol.Ther. ***110*** 415.

$P2Y_{14}$ Agonist

MRS 2690
Cat. No. 2915



MRS 2690 is a potent $P2Y_{14}$ receptor agonist (EC_{50} = 49 nM). The compound displays 7-fold higher potency than UDP-glucose.

Ko *et al* (2007) Structure-activity relationship of uridine 5′-diphosphoglucose analogues as agonists of the human $P2Y_{14}$ receptor. J.Med.Chem. ***50*** 2030.

$P2Y_{14}$ Receptors

The SAR of analogs of UDP-glucose (EC_{50} = 0.35 μM) and UDP at the $P2Y_{14}$ receptor was recently systematically explored.[68] Other naturally occurring UDP-sugars activate this receptor less potently. The 2-thio analog of UDP-glucose, MRS 2690, is a 6-fold more potent agonist for the $P2Y_{14}$ receptor and, unlike UDP-glucose, is inactive at the $P2Y_2$ receptor. The $P2Y_{14}$ receptor is structurally restrictive with respect to modification of the nucleobase, ribose, and phosphate moieties of agonist ligands. However, the glucose moiety may be deleted in UDP analogs, some of which still are very potent in receptor activation. For example, α,β-difluoromethylene-UDP, MRS 2802, is inactive at the $P2Y_6$ receptor and fully activates the human $P2Y_{14}$ receptor with an EC_{50} of 63 nM.

Conclusion

Novel ligands for the P2X and P2Y receptor families are now available for use as tools in pharmacological studies. Selective nucleotide agonist ligands, although typically of low bioavailability and stability *in vivo*, have been designed. Recently, selective antagonist ligands for P2 receptors have been reported as a result of library screening, conversion of agonists into antagonist, and the careful structural modification of known non-selective ligands.

References

1. **Surprenant and North** (2009) Signaling at purinergic P2X receptors. Ann.Rev.Physiol. ***71*** 333.
2. **Abbracchio** *et al* (2006) International Union of Pharmacology LVIII. Update on the P2Y G protein-coupled nucleotide receptors: From molecular mechanisms and pathophysiology to therapy. Pharmacol. Rev. ***58*** 281.
3. **Kawate** *et al* (2009) Crystal structure of the ATP-gated $P2X_4$ ion channel in the closed state. Nature ***460*** 592.
4. **Young** (2009) P2X receptors: dawn of the post-structure era. Trends Biochem.Sci. ***35*** 83.
5. **Carter** *et al* (2009) Quantification of G_i-mediated inhibition of adenylyl cyclase activity reveals that UDP is a potent agonist of the human $P2Y_{14}$ receptor. Mol.Pharmacol. ***76*** 1341.
6. **Ivanov** *et al* (2006) Defining the nucleotide binding sites of P2Y receptors using rhodopsin-based homology modeling. J.Comput.Aided Mol.Des. ***20*** 417.
7. **Hoffmann** *et al* (1999) The role of amino acids in extracellular loops of the human $P2Y_1$ receptor in surface expression and activation processes. J.Biol.Chem. ***274*** 14639.
8. **Hillmann** *et al* (2009) Key determinants of nucleotide-activated G protein-coupled $P2Y_2$ receptor function revealed by chemical and pharmacological experiments, mutagenesis and homology modeling. J.Med.Chem. ***52*** 2762.
9. **Zylberg** *et al* (2007) Structure and ligand-binding site characteristics of the human $P2Y_{11}$ nucleotide receptor deduced from computational modelling and mutational analysis. Biochem.J. ***405*** 277.
10. **Hoffmann** *et al* (2009) Interaction of new, very potent non-nucleotide antagonists with Arg256 of the human platelet P2Y12 receptor. J.Pharmacol.Exp.Ther. ***331*** 648..
11. **Bourdon** *et al* (2006) (*N*)-methanocarba-2MeSADP (MRS2365) is a subtype-specific agonist that induces rapid desensitization of the $P2Y_1$ receptor of human platelets. J. Throm.Haemostas. ***4*** 861.
12. **Ecke** *et al* (2008) Hetero-oligomerization of the $P2Y_{11}$ receptor with the $P2Y_1$ receptor controls the internalization and ligand selectivity of the $P2Y_{11}$ receptor. Biochem.J. ***409*** 107.
13. **Nakata** *et al* (2003) Hetero-oligomerization between adenosine A_1 and $P2Y_1$ receptors in living cells: formation of ATP-sensitive adenosine receptors. Drug Dev. Res. ***58*** 340.
14. **Baqi** *et al* (2010) Development of potent and selective inhibitors of ecto-5´-nucleotidase based on an anthraquinone scaffold. J.Med. Chem. ***53*** 2076.
15. **Houston** *et al* (2006) [^{32}P]2-iodo-*N*^{6}-methyl-(*N*)-methanocarba-2´-deoxyadenosine-3´,5´-bisphosphate ([^{32}P]MRS2500), a novel radioligand for quantification of native $P2Y_1$ receptors. Br. J. Pharmacol. ***147*** 459.
16. **El-Tayeb** *et al* (2005) Synthesis and preliminary evaluation of [^{3}H]PSB-0413, a selective antagonist radioligand for platelet $P2Y_{12}$ receptors. Bioorg.Med.Chem.Lett. ***15*** 5450.
17. **Jarvis** *et al* (2004) [^{3}H]A-317491, a novel high-affinity non-nucleotide antagonist that specifically labels human $P2X_{2/3}$ and $P2X_3$ receptors. J.Pharmacol.Exp.Ther. ***310*** 407.
18. **Jacobson** *et al* (2002) Perspective: Purine and pyrimidine (P2) receptors as drug targets. J.Med.Chem. ***45*** 4057.
19. **Kim** *et al* (2001) Structure activity relationships of pyridoxal phosphate derivatives as potent and selective antagonists of $P2X_1$ receptors. J.Med.Chem. ***44*** 340.
20. **Virginio** *et al* (1998) Trinitrophenyl-substituted nucleotides are potent antagonists selective for $P2X_1$, $P2X_3$ and heteromeric $P2X_{2/3}$ receptors. Mol.Pharmacol. ***53*** 969..
21. **Whittenburg** *et al* (1996) P2-purinoceptor antagonists:II blockade of P2-purinoceptor subtypes and ecto-nuleotidase by compounds related to Evans blue and trypan blue. Naunyn-Schmied.Arch.Pharmacol. ***354*** 491.
22. **Ullmann** *et al* (2005) Synthesis and structure-activity relationships of suramin-derived $P2Y_{11}$ receptor antagonists with nanomolar potency. J.Med.Chem ***48*** 7040.
23. **Rettinger** *et al* (2000) The suramin analogue NF279 is a novel and potent antagonist selective for the $P2X_1$ receptor. Neuropharmacology ***39*** 2044.
24. **Rettinger** *et al* (2005) Profiling at recombinant homomeric and heteromeric rat P2X receptors identifies the suramin analogue NF449 as a highly potent $P2X_1$ receptor antagonist. Neuropharmacology ***48*** 461.
25. **Soto** *et al* (1999) Antagonistic properties of the suramin analogue NF023 at heterologously expressed P2X receptors. Neuropharmacology ***38*** 141.
26. **Jaime-Figueroa** *et al* (2005) Discovery and synthesis of a novel and selective drug-like $P2X_1$ antagonist. Bioorg.Med.Chem.Lett. ***15*** 3292.
27. **Jacobson** *et al* (1998) A pyridoxine cyclic phosphate and its 6-axoaryl derivative selectively potentiate and antagonise activation of $P2X_1$ receptors. J.Med.Chem. ***41*** 2201.
28. **Hausmann** *et al* (2006) The suramin analog 4,4´,4´´,4´´´-(Carbonylbis (imino-5,1,3-benzenetriylbis (carbonylimino)))tetra-kis-benzenesulfonic acid (NF110) potently blocks $P2X_3$ receptors: subtype selectivity is determined by location of sulfonic acid groups. Mol.Pharmacol. ***69*** 2058.
29. **Carter** *et al* (2009) Identification and SAR of novel diaminopyrimidines. Part 1: The discovery of RO-4, a dual $P2X_3$/$P2X_{2/3}$ antagonist for the treatment of pain. Bioorg.Med.Chem.Lett. ***19*** 1628.
30. **Jung** *et al* (2007) Structure-activity relationship studies of spinorphin as a potent and selective human $P2X_3$ receptor antagonist. J.Med.Chem. ***50*** 4543.
31. **Donnelly-Roberts** *et al* (2008) Painful purinergic receptors. J.Pharmacol.Exp.Ther. ***324*** 409.
32. **Silberberg** *et al* (2007) Ivermectin Interaction with Transmembrane Helices Reveals Widespread Rearrangements during Opening of P2X Receptor Channels. Neuron ***54*** 263.
33. **Bo** *et al* (2003) R.A. Pharmacological and Biophysical Properties of the Human $P2X_5$ Receptor. Mol.Pharmacol. ***63*** 1407.
34. **Bianchi** *et al* (1999) Pharmacological characterization of recombinant human and rat P2X receptor subtypes. Eur.J.Pharmacol. ***376*** 127.
35. **Chessell** *et al* (1998) Effects of antagonists at the human recombinant P2X7 receptor. Br.J.Pharmacol. ***124*** 1314.
36. **Donnelly-Roberts** *et al* (2009) Mammalian $P2X_7$ receptor pharmacology: comparison of recombinant mouse, rat and human $P2X_7$ receptors. Br.J.Pharmacol. ***157*** 1203.
38. **Michel** *et al* (2008) Negative and positive allosteric modulators of the $P2X_7$ receptor. Br.J.Pharmacol. ***153*** 737.
39. **Stokes** *et al* (2006) Characterization of a selective and potent antagonist of human $P2X_7$ receptors, AZ11645373. Br.J.Pharmacol. ***149*** 880.
40. **Michel** *et al* (2008) Identification of regions of the $P2X_7$ receptor that contribute to human and rat species differences in antagonist effects. Br.J.Pharmacol. ***155*** 738.
41. **Cattaneo** (2010) New $P2Y_{12}$ inhibitors. Circulation ***121*** 171.
42. **King** *et al* (1999) Diinosine pentaphosphate (IP5I) is a potent antagonist at recombinant rat $P2X_1$ receptors. Br.J.Pharmacol. ***128*** 981.
43. **Eliahu** *et al* (2009) Identification of hydrolytically stable and selective $P2Y_1$ receptor agonists. Eur.J.Med.Chem. ***44*** 1525.
44. **Nandanan** *et al* (1999). Structure activity relationships of bisphosphate nucleotide derivatives as $P2Y_1$ receptor antagonists and partial agonists. J.Med.Chem. ***42*** 1625.
45. **Kim** *et al* (2003) 2-Substitution of adenine nucleotide analogues containing a bicyclo[3.1.0]hexane ring system locked in a Northern conformation: Enhanced potency as $P2Y_1$ receptor antagonists. J.Med. Chem. ***46*** 4974.
46. **Cattaneo** *et al* (2004) Antiaggregatory activity in human platelets of potent antagonists of the $P2Y_1$ receptor. Biochem.Pharmacol. ***68*** 1995.
47. **Hechler** *et al.* (2006) MRS2500 [2-iodo-*N*^{6}-methyl-(*N*)-methanocarba-2´-deoxyadenosine-3´,5´-bisphosphate], a potent, selective and stable antagonist of the $P2Y_1$ receptor, with strong antithrombotic activity in mice. J.Pharm.Exp.Therap. ***316*** 556.
48. **Pfefferkorn** *et al* (2008) $P2Y_1$ receptor antagonists as novel antithrombotic agents. Bioorg.Med.Chem.Lett ***18*** 3338.
49. **Gao** *et al* (2004) 2,2´-Pyridylisatogen tosylate antagonizes $P2Y_1$ receptor signaling without affecting nucleotide binding. Biochem. Pharmacol. ***68*** 231.
50. **Hou** *et al* (2002) Am.J.Phys.Heart and Circ.Phys. ***282*** 784.
51. **Jacobson** *et al* (2006) Structure activity and molecular modeling analyses of ribose- and base-modified uridine 5´-triphosphate analogues at the human $P2Y_2$ and $P2Y_4$ receptors. Biochem. Pharmacol. ***71*** 540.
52. **Ivanov** *et al* (2007) Molecular modeling of the human $P2Y_2$ receptor and design of a selective agonist, 2´-amino-2´-deoxy-2-thio-UTP. J.Med.Chem. ***50*** 1166.
53. **Shaver** *et al* (2005) Structure–activity relationships of dinucleotides: Potent and selective agonists of P2Y receptors. Purinerg. Sig. ***1*** 183.
54. **Ko** *et al* (2008) Synthesis and potency of novel uracil nucleotide analogues as $P2Y_2$ and $P2Y_6$ receptor agonists. Bioorg.Med.Chem. ***16*** 6319.
55. **Kindon** *et al* (1998) World Pat. ***98*** 54180.
56. **Korcok** *et al* (2005) $P2Y_6$ nucleotide receptors activate NF-κB and increase survival of osteoclasts. J.Biol.Chem ***280*** 16909.
57. **El-Tayeb** *et al* (2006) Synthesis and structure-activity relationships of uracil nucleotide derivatives and analogues as agonists at human $P2Y_2$, $P2Y_4$, and $P2Y_6$ receptors. J.Med.Chem ***49*** 7076.
58. **Besada** *et al* (2006) Structure activity relationship of uridine 5´-diphosphate analogues at the human $P2Y_6$ receptor. J. Med. Chem. ***49*** 5532-5543.
59. **Mamedova** *et al* (2004) Diisothiocyanate derivatives as potent, insurmountable antagonists of $P2Y_6$ nucleotide receptors. Biochem. Pharmacol. ***67*** 1763.

60. **Communi** *et al* (1999) Pharmacological characterization of the human $P2Y_{11}$ receptor. Br.J.Pharmacol. ***128*** 1199.
61. **Ullmann** *et al* (2005) Synthesis and structure-activity relationships of suramin-derived $P2Y_{11}$ receptor antagonists with nanomolar potency. J.Med.Chem ***48*** ***7040***.
62. **Savi** *et al* (2002) Identification and biological activity of the active metabolite of Clopidogrel. Throm.Haemostas. ***84*** 891.
63. **Jakubowski** *et al* (2007) A multiple dose study of prasugrel (CS-747), a novel thienopyridine $P2Y_{12}$ inhibitor, compared with clopidogrel in healthy humans. Br.J.Clin Pharmacol. ***63*** 421.
64. **Springthorpe** *et al* (2007) From ATP to AZD6140: the discovery of an orally active reversible $P2Y_{12}$ receptor antagonist for the prevention of thrombosis. Bioorg.Med.Chem Lett. ***17*** 6013.
65. **Ye** *et al* (2008) Carba-nucleosides as Potent Antagonists of the Adenosine 5´-Diphosphate (ADP) Purinergic Receptor ($P2Y_{12}$) on Human Platelets. ChemMedChem ***3*** 732.
66. **Douglass** *et al* (2008) Lipophilic modifications to dinucleoside polyphosphates and nucleotides that confer antagonist properties at the $P2Y_{12}$ platelet receptor. J.Med.Chem. ***51*** 1007.
67. **Kim** *et al* (2005) Synthesis of pyridoxal phosphate derivatives with antagonist activity at the $P2Y_{13}$ receptor. Biochem.Pharmacol. ***70*** 266.
68. **Das** *et al* (2010) Human $P2Y_{14}$ receptor agonists: Truncation of the hexose moiety of uridine-5´-diphosphoglucose and its replacement with alkyl and aryl groups. J.Med.Chem. ***53*** 471.

P2X and P2Y Receptor Compounds Available from Tocris

P2X Receptors

Agonists

3245 **ATP disodium salt**
P2 purinergic agonist

3312 **BzATP triethylammonium salt**
$P2X_7$ agonist. Also $P2X_1$ and $P2Y_1$ partial agonist

3209 **α,β-Methyleneadenosine 5´-triphosphate trisodium salt**
P2-purinoceptor agonist

1062 **2-Methylthioadenosine triphosphate tetrasodium salt**
P2 purinergic agonist

Antagonists

2972 **A 438079 hydrochloride**
Competitve $P2X_7$ antagonist

3701 **A 740003**
Potent and selective $P2X_7$ antagonist

3323 **AZ 10606120 dihydrochloride**
Potent $P2X_7$ receptor antagonist

3317 **AZ 11645373**
Potent and selective human $P2X_7$ antagonist

3579 **5-BDBD**
Potent $P2X_4$ receptor antagonist

0845 **Evans Blue tetrasodium salt**
Selective P2X purinergic antagonist

1277 **KN-62**
Non-competitive $P2X_7$ antagonist

1240 **NF 023**
Selective, competitive P2X antagonist

2548 **NF 110**
Potent $P2X_3$ antagonist

2450 **NF 157**
Selective $P2Y_{11}/P2X_1$ antagonist

1199 **NF 279**
Potent and selective $P2X_1$ antagonist

1391 **NF 449**
Highly selective $P2X_1$ antagonist

0625 **PPADS tetrasodium salt**
P2 purinergic antagonist

0683 ***iso*-PPADS tetrasodium salt**
P2X antagonist

1309 **PPNDS**
Potent, selective $P2X_1$ antagonist

3052 **RO-3**
Selective $P2X_3$ and $P2X_{2/3}$ antagonist

2931 **Spinorphin**
Potent $P2X_3$ antagonist

1472 **Suramin hexasodium salt**
Non-selective P2 antagonist

2464 **TNP-ATP triethylammonium salt**
Potent, selective P2X antagonist

Modulators

3385 **GW 791343 trihydrochloride**
$P2X_7$ allosteric modulator

1260 **Ivermectin**
Positive allosteric modulator for $P2X_4$ receptor

Other

1203 **MRS 2219**
Potentiates $P2X_1$-mediated responses

P2Y Receptors

Agonists

3245 **ATP disodium salt**
P2 agonist

3312 **BzATP triethylammonium salt**
$P2Y_1$ partial agonist. Also $P2X_7$ agonist and $P2X_1$ partial agonist

3209 **α,β-Methyleneadenosine 5´-triphosphate trisodium salt**
P2 agonist

1062 **2-Methylthioadenosine triphosphate tetrasodium salt**
P2 agonist

1624 **2-Methylthio-ADP trisodium salt**
Potent agonist for $P2Y_1$, $P2Y_{12}$ and $P2Y_{13}$

2157 **MRS 2365**
Highly potent and selective $P2Y_1$ agonist

2915 **MRS 2690**
Potent $P2Y_{14}$ agonist

3884 **MRS 2768 tetrasodium salt**
Selective $P2Y_2$ agonist

2715 **PSB 0474**
Potent and selective $P2Y_6$ agonist

3279 **UTPγS trisodium salt**
Selective $P2Y_{2/4}$ agonist

3280 **2-ThioUTP tetrasodium salt**
Potent and selective $P2Y_2$ agonist

Antagonists

3321 **AR-C 66096 tetrasodium salt**
Potent and selective $P2Y_{12}$ antagonist

2490 **(±)-Clopidogrel hydrochloride**
Selective $P2Y_{12}$ antagonist

0900 **MRS 2179 tetrasodium salt**
Selective $P2Y_1$ antagonist

2402 **MRS 2211**
Competitive $P2Y_{13}$ antagonist

2158 **MRS 2279**
Selective, high affinity $P2Y_1$ antagonist

2159 **MRS 2500 tetraammonium salt**
Extremely potent and selective $P2Y_1$ antagonist

2146 **MRS 2578**
Selective $P2Y_6$ antagonist

2450 **NF 157**
Selective $P2Y_{11}/P2X_1$ antagonist

1682 **PIT**
P2Y ligand; displays mixed antagonism/potentiation

0625 **PPADS tetrasodium salt**
P2 antagonist

1472 **Suramin hexasodium salt**
Non-selective P2 antagonist

3111 **UDP disodium salt**
Endogenous ligand; competitive antagonist at $P2Y_{14}$ receptors

Related Products

1283 **ARL 67156 trisodium salt**
Ecto-ATPase inhibitor

1745 **5-Iodotubercidin**
Nucleoside transporter inhibitor. Also a broad spectrum kinase inhibitor

2924 **NBMPR**
Equilibrative nucleoside transporter 1 (ENT1) inhibitor

2689 **POM 1**
Inhibitor of E-NTPDases

2573 **PSB 069**
Non-selective NTPDase inhibitor

2574 **PSB 06126**
NTPDase 3 inhibitor

For a complete and up-to-date product listing please visit www.tocris.com.

Tocris Reviews No. 33

TOCRIS bioscience
www.tocris.com

UK:
Phone: + 44 (0)117 916 3333
Fax: + 44 (0)117 916 3344
customerservice@tocris.co.uk
Tocris House, IO Centre, Moorend Farm Avenue,
Avonmouth, Bristol, BS11 0QL, UK

US:
Phone: 800-421-3701
Fax: 800-483-1993
customerservice@tocrisusa.com
16144 Westwoods Business Park,
Ellisville, Missouri 63021 USA